

Edgar Filing: ALFACELL CORP - Form 8-K

ALFACELL CORP  
Form 8-K  
October 24, 2006

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 24, 2006

ALFACELL CORPORATION  
(Exact name of registrant as specified in its charter)

0-11088  
(Commission File Number)

Delaware  
(State or other jurisdiction of incorporation)

22-2369085  
(I.R.S. Employer Identification No.)

225 BELLEVILLE AVENUE, BLOOMFIELD, NEW JERSEY 07003  
(Address of principal executive offices, with zip code)

(973) 748-8082  
(Registrant's telephone number, including area code)

NOT APPLICABLE  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (SEE General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1

ITEM 8.01 OTHER EVENTS.

On October 24, 2006, Alfacell Corporation (the "Company") issued a press release announcing results from further detailed analysis of the Company's previously reported Phase IIIa clinical trial of ONCONASE(R) (ranpirnase) versus doxorubicin for the treatment of unresectable malignant mesothelioma (UMM). A

Edgar Filing: ALFACELL CORP - Form 8-K

copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

99.1 Press release of Alfacell Corporation dated October 24, 2006.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALFACELL CORPORATION

Date: October 24, 2006

By: /s/ Robert D. Love  
Robert D. Love  
Chief Financial Officer

3